Research Antibodies

 
News Articles for Research Antibodies top ^
2013/3/5
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) , a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced a second agreement to expand WuXi’s use of OMT’s OmniRat™ and OmniMouse™ technologies to strengthen the development and commercial opportunities for WuXi’s Asian regional and global clients.
Sign-up for WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies investment picks
2013/5/6
BERKELEY, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) , a leader in the discovery and development of therapeutic antibodies, announced today that Paul Rubin, the Company's Senior Vice President, Research and Development, and Chief Medical Officer, is scheduled to present at the Credit Suisse 2013 Antibody Day on May 10, 2013 at 8:30 a.m. Eastern time.
Sign-up for XOMA to Present at Credit Suisse 2013 Antibody Day investment picks
2013/5/6
NEEDHAM, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will present an overview of the Company's antibody technology and pipeline at the Credit Suisse Antibody Day on Friday, May 10, 2013 at 11:00 am ET in New York.
Sign-up for Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody Day investment picks
2013/3/4
NEWARK, Del.
Sign-up for iBio Adds New Therapeutic Antibody to Its Pipeline investment picks
2013/3/13
Development License and Option Agreement Represents Blueprint for Innovation between Pharma and Biotech SAN DIEGO , March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV) .
Sign-up for Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease investment picks
2013/3/18
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI ® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy (PML) is detected early.
Sign-up for New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status investment picks
2013/4/9
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented in multiple sessions at the 104 th Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. Three data presentations highlight the rapid progress being made in ADC technology and testing.
Sign-up for Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR investment picks
2013/4/29
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Credit Suisse First Annual Antibody Day in New York on May 10, 2013 at 9:30 AM Eastern.
Sign-up for Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody Day investment picks
2013/3/18
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=997963&ProfileId=051205&sourceType=1 AURORA, ONTARIO --
Sign-up for Helix BioPharma Corp. Announces L-DOS47 Scientific Presentation to Be Made at BIT LifeScience's 5th International Congress of Antibodies investment picks
2013/4/3
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1003290&ProfileId=051205&sourceType=1 GLOSTRUP, DENMARK --
Sign-up for Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer investment picks
2013/4/5
OPKO Health, Inc. (NYSE: OPK) today announced the publication of a study applying its novel library screening technology to identify a synthetic peptoid that binds to anti-Aquaporin 4 (AQP4) antibodies in the serum of patients with Neuromyelitis optica (NMO). The study, published in the March 21, 2013 issue of the journal, Chemistry and Biology , reports on the ability to distinguish between NMO patient serum and serum from healthy controls or patients with multiple sclerosis, Alzheimer’s Disease, narcolepsy, and lupus with high accuracy using the Company’s powerful and general method for the identification in small blood samples of disease-specific antibodies that can serve as diagnostic biomarkers for various diseases.
Sign-up for OPKO Health Announces Publication of Study Detecting Antibodies in NMO Patients Using OPKO Screening Technology investment picks
2013/4/9
Amorfix announces breakthrough scientific discovery and provides update for its ovarian cancer therapeutic antibody program Canada NewsWire TSX: AMF TORONTO , April 9, 2013 /CNW/ - Amorfix Life Sciences announced today it has completed a study that shows that the treatment of cancer cells with chemotherapeutic agents increases the amount of misfolded prion protein at the cell surface, and the subsequent binding of anti-prion protein antibodies.
Sign-up for Amorfix announces breakthrough scientific discovery and provides update for its ovarian cancer therapeutic antibody program investment picks
2013/4/8
-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) -- WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) --  Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company's patented DOCK-AND-LOCK™ (DNL™) platform technology.
Sign-up for Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy investment picks
2013/4/10
WASHINGTON, April 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the development of novel T-cell redirecting agents made as DOCK-AND-LOCK™ (DNL™) complexes by tethering a single-chain variable fragment (scFv) that binds to CD3 on T cells to different antibody fragments that target tumor antigens.
Sign-up for Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors investment picks
2013/4/23
DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA) , a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the successful first patient dosing in a Phase 1 clinical trial of its antibody therapeutic candidate, NEOD001.
Sign-up for First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis investment picks
2013/3/2
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology PARIS and TARRYTOWN, N.Y. , March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/ SAR231893 ), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami .
Sign-up for Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis investment picks
2013/4/23
Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22.
Sign-up for Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis investment picks
2013/5/3
SAN DIEGO , May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.
Sign-up for Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates investment picks
2013/5/8
SOUTH SAN FRANCISCO, Calif.
Sign-up for KaloBios to Present at Credit Suisse Antibody Conference investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Antibodies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Analysts  |  Next: Research Applications